Gallbladder Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Gallbladder Cancer – Pipeline Review, H2 2016’, provides an overview of the Gallbladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gallbladder Cancer

The report reviews pipeline therapeutics for Gallbladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gallbladder Cancer therapeutics and enlists all their major and minor projects

The report assesses Gallbladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gallbladder Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

harma Inc

BeiGene Ltd

Eli Lilly and Company

Novartis AG

VasGene Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gallbladder Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Gallbladder Cancer - Overview 7

Pipeline Products for Gallbladder Cancer - Comparative Analysis 8

Gallbladder Cancer - Therapeutics under Development by Companies 9

Gallbladder Cancer - Therapeutics under Investigation by Universities/Institutes 10

Gallbladder Cancer - Pipeline Products Glance 11

Clinical Stage Products 11

Gallbladder Cancer - Products under Development by Companies 12

Gallbladder Cancer - Products under Investigation by Universities/Institutes 13

Gallbladder Cancer - Companies Involved in Therapeutics Development 14

4SC AG 14

harma Inc 14

BeiGene Ltd 16

Eli Lilly and Company 17

Novartis AG 18

VasGene Therapeutics Inc 19

Gallbladder Cancer - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

BGBA-317 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

binimetinib - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

copanlisib hydrochloride - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

DKN-01 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

merestinib - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ramucirumab - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

resminostat - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

trametinib dimethyl sulfoxide - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Vas-01 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Gallbladder Cancer - Dormant Projects 71

Gallbladder Cancer - Discontinued Products 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for Gallbladder Cancer, H2 2016 7

Number of Products under Development for Gallbladder Cancer – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Gallbladder Cancer – Pipeline by 4SC AG, H2 2016 14

Gallbladder Cancer – Pipeline by Array BioPharma Inc, H2 2016 15

Gallbladder Cancer – Pipeline by Bayer AG, H2 2016 15

Gallbladder Cancer – Pipeline by BeiGene Ltd, H2 2016 16

Gallbladder Cancer – Pipeline by Eli Lilly and Company, H2 2016 17

Gallbladder Cancer – Pipeline by Novartis AG, H2 2016 18

Gallbladder Cancer – Pipeline by VasGene Therapeutics Inc, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Gallbladder Cancer – Dormant Projects, H2 2016 71

Gallbladder Cancer – Discontinued Products, H2 2016 72

List of Figures

List of Figures

Number of Products under Development for Gallbladder Cancer, H2 2016 7

Number of Products under Development for Gallbladder Cancer – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports